Biomarkers for diagnosis and prognosis of lung cancer
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 9, 2020
Grant Date -
Mar 15, 2018
app pub date -
Sep 14, 2017
filing date -
Sep 14, 2016
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Provided herein are methods for non-invasively diagnosing and/or prognosing a lung cancer and for determining the efficacy of a therapeutic treatment regimen for the lung cancer. Expression levels of at least two small non-coding RNAs, for example, microRNAs and small nucleolar RNAs, are measured and used to calculate an area under the curve (AUC) that provides a probability of lung cancer in the subject. The smoking history of the subject and, if present, the size of pulmonary nodules may be incorporated into the calculation.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully